Christopher T. Giordano's most recent trade in Tenax Therapeutics Inc was a trade of 8,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on July 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2026 | 8,500 | 1,241,500 | - | - | Stock Option (right to buy) | |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.94 per share. | 13 Jul 2026 | 8,500 | 11,324 (0%) | 0% | 5.9 | 50,490 | Common Stock |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2026 | 219 | 218 | - | - | Stock Option (right to buy) | |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.55 per share. | 13 Jul 2026 | 219 | 2,824 (0%) | 0% | 3.5 | 777 | Common Stock |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 450,000 | 450,000 | - | - | Stock Option (right to buy) | |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Purchase of securities on an exchange or from another person at price $ 7.75 per share. | 18 Nov 2025 | 1,612 | 1,612 (0%) | 0% | 7.8 | 12,500 | Common Stock |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Purchase of securities on an exchange or from another person at price $ 7.59 per share. | 18 Nov 2025 | 538 | 2,605 (0%) | 0% | 7.6 | 4,083 | Common Stock |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Purchase of securities on an exchange or from another person at price $ 7.51 per share. | 18 Nov 2025 | 455 | 2,067 (0%) | 0% | 7.5 | 3,417 | Common Stock |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 1,400,000 | 1,400,000 | - | - | Stock Option (right to buy) | |
| Tenax Therapeutics Inc | Giordano T. Christopher | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 1,250,000 | 1,250,000 | - | - | Stock Option (right to buy) | |
| Tenax Therapeutics Inc | Christopher T. Giordano | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 437 | 437 | - | - | Stock Option (right to buy) |